JP5985481B2 - 抗イディオタイプ抗体の迅速な産生 - Google Patents

抗イディオタイプ抗体の迅速な産生 Download PDF

Info

Publication number
JP5985481B2
JP5985481B2 JP2013527272A JP2013527272A JP5985481B2 JP 5985481 B2 JP5985481 B2 JP 5985481B2 JP 2013527272 A JP2013527272 A JP 2013527272A JP 2013527272 A JP2013527272 A JP 2013527272A JP 5985481 B2 JP5985481 B2 JP 5985481B2
Authority
JP
Japan
Prior art keywords
antibody
igg2a
antibodies
idiotype
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013527272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538812A5 (da
JP2013538812A (ja
Inventor
ロバート ジェイ． ダン，
ロバート ジェイ． ダン，
マリリン アール． ケリー，
マリリン アール． ケリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2013538812A publication Critical patent/JP2013538812A/ja
Publication of JP2013538812A5 publication Critical patent/JP2013538812A5/ja
Application granted granted Critical
Publication of JP5985481B2 publication Critical patent/JP5985481B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013527272A 2010-09-01 2011-08-31 抗イディオタイプ抗体の迅速な産生 Active JP5985481B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37908910P 2010-09-01 2010-09-01
US61/379,089 2010-09-01
PCT/US2011/050001 WO2012030982A1 (en) 2010-09-01 2011-08-31 Rapid generation of anti-idiotypic antibodies

Publications (3)

Publication Number Publication Date
JP2013538812A JP2013538812A (ja) 2013-10-17
JP2013538812A5 JP2013538812A5 (da) 2014-10-16
JP5985481B2 true JP5985481B2 (ja) 2016-09-06

Family

ID=44645832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527272A Active JP5985481B2 (ja) 2010-09-01 2011-08-31 抗イディオタイプ抗体の迅速な産生

Country Status (7)

Country Link
US (1) US10150817B2 (da)
EP (1) EP2611834B1 (da)
JP (1) JP5985481B2 (da)
AU (1) AU2011295968B2 (da)
DK (1) DK2611834T3 (da)
IL (1) IL224974A (da)
WO (1) WO2012030982A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188864A2 (en) * 2012-06-15 2013-12-19 Sinomab Bioscience Limited Anti-cd22 anti-idiotypic antibodies and uses thereof
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
EP2787008B1 (en) * 2013-04-02 2019-09-04 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-C-met antibody
US10435453B2 (en) 2014-02-07 2019-10-08 Mcmaster University Trifunctional T cell-antigen coupler and methods and uses thereof
EP3694997A4 (en) 2017-10-12 2021-06-30 Mcmaster University T-CELL ANTIGEN COUPLER WITH Y182T MUTATION, AND PROCEDURES AND USES THEREOF
JP7357012B2 (ja) * 2018-06-14 2023-10-05 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
WO2021113776A1 (en) * 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
US20230181636A1 (en) * 2020-03-18 2023-06-15 The Rockefeller University Antibody gene editing in b lymphocytes and co-expression of cargo protein
US20220064335A1 (en) * 2020-08-25 2022-03-03 Crispr Therapeutics Ag Anti-idiotype antibodies targeting anti-bcma chimeric antigen receptor
WO2022256449A1 (en) 2021-06-01 2022-12-08 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
PT89107A (pt) * 1987-11-30 1989-11-30 Idec Pharma Corp Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
AU1025692A (en) * 1991-02-06 1992-08-13 Ciba-Geigy Ag Novel chimeric antiidiotypic monoclonal antibodies
EP0502416B1 (en) 1991-03-04 1997-12-03 American Cyanamid Company Stimulation of growth with anti-idiotypic antibodies raised against an antibody specific for porcine somatotropin
ES2133395T3 (es) * 1992-05-22 1999-09-16 Novartis Ag Anticuerpos monoclonales anti-idiotipicos contra el anticuerpo monoclonal especifico lewis y- br55-2, y sus usos.
WO1998026086A1 (en) * 1996-12-11 1998-06-18 University Of Florida Novel methods and compositions for treatment of autoimmune diseases
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
US20030072762A1 (en) 2001-08-03 2003-04-17 Van De Winkel Jan G. J. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies
EP1511772B1 (en) * 2002-05-28 2011-11-23 Omrix Biopharmaceuticals Inc. Method for obtaining anti-idiotype antibodies
WO2007064911A1 (en) 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof

Also Published As

Publication number Publication date
AU2011295968B2 (en) 2017-01-05
EP2611834A1 (en) 2013-07-10
IL224974A (en) 2017-10-31
US20130330323A1 (en) 2013-12-12
AU2011295968A1 (en) 2013-03-21
US10150817B2 (en) 2018-12-11
JP2013538812A (ja) 2013-10-17
WO2012030982A1 (en) 2012-03-08
DK2611834T3 (da) 2018-06-18
EP2611834B1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
JP5985481B2 (ja) 抗イディオタイプ抗体の迅速な産生
KR102389083B1 (ko) 항-cd47 항체 및 그 용도
US11655296B2 (en) Anti-CD47 antibody and use thereof
JP6306070B2 (ja) 進行型多発性硬化症の治療方法
US11525007B2 (en) Antibody fab and Fc variants
AU2020289179B2 (en) Binding molecule specific for CD73 and use of binding molecule
US20210032350A1 (en) Antibodies to galectin-3 and methods of use thereof
CN114642731A (zh) 施用β7整联蛋白拮抗剂的方法
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
US20220403022A1 (en) Anti-TIGIT Antibodies and Uses Thereof
US11629184B2 (en) Calcitonin gene-related peptide (CGRP) antagonist antibodies
US20230078601A1 (en) Anti-mullerian hormone receptor 2 antibodies and methods of use
JP2011501734A (ja) オクレリズマブ（２ｈ７）の単回一定注入投与量
JP2019519544A (ja) 炎症性腸疾患を治療する方法
US20230242646A1 (en) Humanized Anti-Human CD89 Antibodies and Uses Thereof
EP4285936A1 (en) Antibody-drug conjugate and medical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160803

R150 Certificate of patent or registration of utility model

Ref document number: 5985481

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250